Stereotactic radiosurgery for craniopharyngioma is usually a high risk procedure due to the intimate relationship of the tumour to the optic chiasm and conservative dosing has been advocated to reduce complication rates. In 2002, in a publication from Karolinska Hospital, Sweden, 13 out of 21 patients received only a marginal dose of 6 Gy (not considered a radical dose) and 11 out of 13 tumours progressed. This recent report must argue against single dose stereotactic radiosurgery as the primary radiation therapy modality in most cases. However, where the disease is 'away' from the optic apparatus, such constraints do not apply. We here report the successful treatment of three consecutive patients whose craniopharyngioma was confined to the pituitary fossa, and a finite distance from the optic pathways and in whom optimal dosing was employed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/0268869031000108864 | DOI Listing |
JCEM Case Rep
February 2025
Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX 77030, USA.
A 65-year-old patient presented with recurrent, locally advanced poorly differentiated thyroid cancer despite 2 neck surgeries, and with newly diagnosed brain and skull base metastases. He was treated with palliative stereotactic radiosurgery to the brain and skull base lesions. Thereafter, as no targetable genetic alteration was identified and antiangiogenic multikinase inhibitors were deemed at high risk of hemorrhagic complications, off-label systemic therapies were considered.
View Article and Find Full Text PDFFront Neurol
January 2025
Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Refractory cancer pain affects 10-20% of patients with advanced malignancies and is not adequately controlled by opioids. The intrathecal therapy is an effective interventional procedure for referral, but the implanted infusion pumps are costly and the refilling requires technical expertise. Hypophysectomy, in its three stages-surgical, chemical, and radiosurgical-has emerged as an alternative for managing this pain.
View Article and Find Full Text PDFMed Dosim
January 2025
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Most of conventional 2-dimensional (2D) methods verify dose of multiple targets separately one-by-one for Single-isocenter Multiple-target (SIMT) brain plans, which are inefficient and sub-optimal. This study presented a practical method to verify the dose of 2 targets simultaneously for improved efficiency and accuracy. Fifteen Stereotactic Radiation Therapy (SRT) and sixteen Stereotactic Radiosurgery (SRS) plans were used for this study.
View Article and Find Full Text PDFWorld Neurosurg
January 2025
Department of Neurologic Surgery, Pontificia Universidad Javeriana, Neurosurgery Research Group.
Objective: To compare the rates of postoperative hemorrhages for aneurysms associated with brain AVM evaluating the lesion that was initially treated.
Methods: A systematic review of the literature was carried out following the PRISMA guidelines. The search was performed in PubMed, Embase and Scopus .
Clin Nutr ESPEN
January 2025
Department of Experimental and Clinical Biomedical sciences "Mario Serio", University of Florence, Florence, Italy; Azienda Ospedaliero-Universitaria Careggi, Radiation Oncology Unit, Florence, Italy.
Purpose: Multiple inflammatory and nutritional biomarkers have been established as independent prognostic factors across various solid tumors, but their role in outcomes prediction for glioma is still under investigation. Aim of the present systematic review is to report the available evidence regarding the impact of nutritional assessment and intervention for glioma prognosis and patients' quality of life (QoL).
Materials And Methods: Our systematic review conformed to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!